Background: Up to 40% of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect). Material and Methods: We retrospectively analyzed all our MM patients treated with IO within 6 months before/after brain RT between 2012 and 2016. Progression-free (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with those of controls treated with IO during the same period. Results: Thirty-six cases and 25 controls were identified. Among cases, 23 patients received an anti-CTLA4 agent and 13 an anti-PD1 agent. Eighteen cases were treated with stereotactic RT and 18 with whole-brain RT. Median PFS from the beginning of RT was 4 months in first-line and 2 months in second-line treatment. A third of the cases progressed at first evaluation after RT. Median OS from the beginning of RT was 7 months in first-line and 4 months in second-line treatment. Median PFS and OS of each treatment line showed a trend towards inferiority compared with those of controls. Conclusion: Synergism between RT and IO was not observed in our case series. No cases of abscopal effect were seen, and most patients underwent early systemic progression after RT.

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis / G. Galli, S. Cavalieri, L. Di Guardo, C. Cimminiello, F. Nichetti, F. Corti, M. Garcia, B. Pappalardi, C. Fallai, F. de Braud, M. Platania, M. Del Vecchio. - In: ONCOLOGY RESEARCH AND TREATMENT. - ISSN 2296-5262. - 42:4(2019 Apr 01), pp. 182-188. [10.1159/000497211]

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis

G. Galli
Primo
;
S. Cavalieri
Secondo
;
F. Nichetti;F. Corti;F. de Braud;M. Platania
Penultimo
;
M. Del Vecchio
Ultimo
2019

Abstract

Background: Up to 40% of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect). Material and Methods: We retrospectively analyzed all our MM patients treated with IO within 6 months before/after brain RT between 2012 and 2016. Progression-free (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with those of controls treated with IO during the same period. Results: Thirty-six cases and 25 controls were identified. Among cases, 23 patients received an anti-CTLA4 agent and 13 an anti-PD1 agent. Eighteen cases were treated with stereotactic RT and 18 with whole-brain RT. Median PFS from the beginning of RT was 4 months in first-line and 2 months in second-line treatment. A third of the cases progressed at first evaluation after RT. Median OS from the beginning of RT was 7 months in first-line and 4 months in second-line treatment. Median PFS and OS of each treatment line showed a trend towards inferiority compared with those of controls. Conclusion: Synergism between RT and IO was not observed in our case series. No cases of abscopal effect were seen, and most patients underwent early systemic progression after RT.
brain; immunotherapy; melanoma; metastasis; radiotherapy
Settore MED/06 - Oncologia Medica
5-mar-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Manuscript CLEANED 3.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 337.6 kB
Formato Adobe PDF
337.6 kB Adobe PDF Visualizza/Apri
Supplementary Tables.pdf

accesso aperto

Tipologia: Altro
Dimensione 187.65 kB
Formato Adobe PDF
187.65 kB Adobe PDF Visualizza/Apri
Table.pdf

accesso aperto

Tipologia: Altro
Dimensione 185.1 kB
Formato Adobe PDF
185.1 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/647569
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
social impact